Laura Solé
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Laura Solé has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Lluis Espinosa
Program in Cancer Research. Hospital del Mar Research Institute
11 shared publications Mar Iglesias
Hospital del Mar
7 shared publications- Anna Bigas
Institut Hospital del Mar d'Investigacions Mediques Barcelona
6 shared publications - Ángela Montoto
Hospital del Mar Research Institute
5 shared publications - Alberto Villanueva
Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet del Llobregat, Barcelona, Spain
4 shared publications - Daniel Alvarez-Villanueva
IMIM
4 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by Springer Nature in Research Square
PRC2 and MYC repression drives oncofetal reprogramming and autophagy dependence in Colorectal Cancer
The emergence of an oncofetal phenotype in colorectal cancer (CRC) has been linked to therapy resistance and metastatic progression. However, whether this state pre-exists in treatment-naïve tumors or is primarily acquired upon chemotherapy, and the molecular mechanisms underlying these transitions, remain incompletely understood. While transcriptional regulators such as YAP1 and AP1 have been proposed as oncofetal inducers, the epigenetic and metabolic determinants of this process are not fully defined. Here, we integrate transcriptomic analyses from multiple CRC patient cohorts with functional studies in patient-derived organoids (PDOs) to show that both intrinsic and therapy-induced fetal-like CRC states are characterized by coordinated repression of Polycomb Repressive Complex 2 (PRC2) and MYC signaling. This repression involves coordinated downregulation of core and accessory PRC2 components together with attenuation of MYC/MAX activity across patient datasets and experimental models. Functional inhibition of PRC2 is sufficient to unlock fetal and epithelial-to-mesenchymal transition (EMT) transcriptional programs, whereas MYC suppression, mediated in part by MXD1 induction, promotes growth arrest and metabolic adaptation without recapitulating the full fetal signature. Mechanistically, fetal-like CRC cells, irrespective of their origin, display suppression of MYC- and mTOR-driven programs and increased reliance on autophagy. While basal autophagy levels show limited predictive value, induction of fetal-like states by chemotherapy or PRC2 inhibition consistently sensitizes CRC cells to lysosomal blockade. Together, these findings identify PRC2 and MYC repression as convergent regulatory features of oncofetal reprogramming in CRC and reveal autophagy dependence as a context-specific and therapeutically exploitable vulnerability of this aggressive tumor state.
- 20 March 2026
- Published by Springer Nature in Research Square
Open AccessPRC2 and MYC repression drives oncofetal reprogramming and autophagy dependence in Colorectal Cancer
The emergence of an oncofetal phenotype in colorectal cancer (CRC) has been linked to therapy resistance and metastatic progression. However, whether this state pre-exists in treatment-naïve tumors or is primarily acquired upon chemotherapy, and the molecular mechanisms underlying these transitions, remain incompletely understood. While transcriptional regulators such as YAP1 and AP1 have been proposed as oncofetal inducers, the epigenetic and metabolic determinants of this process are not fully defined. Here, we integrate transcriptomic analyses from multiple CRC patient cohorts with functional studies in patient-derived organoids (PDOs) to show that both intrinsic and therapy-induced fetal-like CRC states are characterized by coordinated repression of Polycomb Repressive Complex 2 (PRC2) and MYC signaling. This repression involves coordinated downregulation of core and accessory PRC2 components together with attenuation of MYC/MAX activity across patient datasets and experimental models. Functional inhibition of PRC2 is sufficient to unlock fetal and epithelial-to-mesenchymal transition (EMT) transcriptional programs, whereas MYC suppression, mediated in part by MXD1 induction, promotes growth arrest and metabolic adaptation without recapitulating the full fetal signature. Mechanistically, fetal-like CRC cells, irrespective of their origin, display suppression of MYC- and mTOR-driven programs and increased reliance on autophagy. While basal autophagy levels show limited predictive value, induction of fetal-like states by chemotherapy or PRC2 inhibition consistently sensitizes CRC cells to lysosomal blockade. Together, these findings identify PRC2 and MYC repression as convergent regulatory features of oncofetal reprogramming in CRC and reveal autophagy dependence as a context-specific and therapeutically exploitable vulnerability of this aggressive tumor state.
- Open Access
- 3 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Tight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases
Colorectal cancer (CRC) frequently develops aggressive metastatic disease, yet the cellular features that enable dissemination remain poorly defined. IKKα, a kinase traditionally linked to stress and inflammatory signaling, is increasingly recognized for broader functions in cancer. Here, we show that loss of IKKα unexpectedly promotes metastasis in CRC. Using patient-derived organoids, we find that genetic or pharmacological inhibition of IKKα stabilizes tight-junction components, leading to the emergence of compact epithelial clusters with a heightened ability to spread and colonize the liver. Single-cell transcriptomics reveals expansion of a CDH17⁺/CLDN2⁺ epithelial subpopulation that dominates metastatic lesions, a finding validated by tissue staining. Remarkably, disrupting CLDN2 completely eliminates the metastatic advantage caused by IKKα loss. These results identify a metastasis-competent epithelial state driven by tight-junction remodeling and uncover a vulnerable node that may be exploited therapeutically in aggressive colorectal cancer.
- 3 January 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessTight junction-high and CDH17-positive cell population is the source of colorectal cancer liver metastases
Colorectal cancer (CRC) frequently develops aggressive metastatic disease, yet the cellular features that enable dissemination remain poorly defined. IKKα, a kinase traditionally linked to stress and inflammatory signaling, is increasingly recognized for broader functions in cancer. Here, we show that loss of IKKα unexpectedly promotes metastasis in CRC. Using patient-derived organoids, we find that genetic or pharmacological inhibition of IKKα stabilizes tight-junction components, leading to the emergence of compact epithelial clusters with a heightened ability to spread and colonize the liver. Single-cell transcriptomics reveals expansion of a CDH17⁺/CLDN2⁺ epithelial subpopulation that dominates metastatic lesions, a finding validated by tissue staining. Remarkably, disrupting CLDN2 completely eliminates the metastatic advantage caused by IKKα loss. These results identify a metastasis-competent epithelial state driven by tight-junction remodeling and uncover a vulnerable node that may be exploited therapeutically in aggressive colorectal cancer.
- 11 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (877) , eadr0128
NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage
The DNA damage repair kinase ATM is phosphorylated by the NF-κB pathway kinase IKKα, resulting in enhanced DNA damage repair through the nonhomologous end-joining pathway. Thus, inhibition of IKKα enhances the efficacy of cancer therapy based on inducing DNA damage. Here, we found a role for the IKK regulatory subunit NEMO in DNA damage repair mediated by ATM and IKKα. Exposure to damaging agents induced the interaction of NEMO with a preformed ATM-IKKα complex, which was required to target active ATM and IKKα to chromatin for efficient DNA damage repair but not for activating ATM. Recognition of damaged DNA by the IKKα-NEMO-ATM complex was facilitated by the interaction between NEMO and histones and depended on the ADP ribosylation of histones by the enzyme PARP1. NEMO-deficient cells showed increased activity of the kinase ATR, and inhibition of ATR potentiated the effect of chemotherapy in cells lacking NEMO or IKKα. Bioinformatic analysis of colorectal cancer datasets demonstrated that the expression of genes encoding IKKα, NEMO, and ATM correlated with poor patient prognosis, suggesting that the mechanism linking these three elements may be clinically relevant.
- 11 March 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Signaling
- Vol. 18 (877) , eadr0128
NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage
The DNA damage repair kinase ATM is phosphorylated by the NF-κB pathway kinase IKKα, resulting in enhanced DNA damage repair through the nonhomologous end-joining pathway. Thus, inhibition of IKKα enhances the efficacy of cancer therapy based on inducing DNA damage. Here, we found a role for the IKK regulatory subunit NEMO in DNA damage repair mediated by ATM and IKKα. Exposure to damaging agents induced the interaction of NEMO with a preformed ATM-IKKα complex, which was required to target active ATM and IKKα to chromatin for efficient DNA damage repair but not for activating ATM. Recognition of damaged DNA by the IKKα-NEMO-ATM complex was facilitated by the interaction between NEMO and histones and depended on the ADP ribosylation of histones by the enzyme PARP1. NEMO-deficient cells showed increased activity of the kinase ATR, and inhibition of ATR potentiated the effect of chemotherapy in cells lacking NEMO or IKKα. Bioinformatic analysis of colorectal cancer datasets demonstrated that the expression of genes encoding IKKα, NEMO, and ATM correlated with poor patient prognosis, suggesting that the mechanism linking these three elements may be clinically relevant.
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1, Supplementary methods
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Figure S1, Figure S2, Figure S3, Figure S4, Figure S5, Figure S6, Table S1, Supplementary methods
- Open Access
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Data from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose:Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer.Experimental Design:We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment.Results:We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI.Conclusions:Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 1 October 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose:Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer.Experimental Design:We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment.Results:We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI.Conclusions:Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 30 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4505-4516
Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose: Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer. Experimental Design: We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment. Results: We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI. Conclusions: Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 30 July 2024
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 30 (19) , 4505-4516
Cervical Cancer Evades the Host Immune System through the Inhibition of Type I Interferon and CXCL9 by LIF
Purpose: Cervical cancer is a viral-associated tumor caused by the infection with the human papilloma virus. Cervical cancer is an immunogenic cancer that expresses viral antigens. Despite being immunogenic, cervical cancer does not fully respond to immune checkpoint inhibitors (ICI). LIF is a crucial cytokine in embryo implantation, involved in maternal tolerance that acts as an immunomodulatory factor in cancer. LIF is expressed in cervical cancer and high levels of LIF is associated with poor prognosis in cervical cancer. Experimental Design: We evaluated the impact of LIF on the immune response to ICI using primary plasmocytoid dendritic cells (pDC) and macrophage cultures, syngeneic animals and patient-derived models that recapitulate the human tumor microenvironment. Results: We found that the viral proteins E6 and E7 induce the expression of LIF via the NFκB pathway. The secreted LIF can then repress type I interferon expressed in pDCs and CXCL9 expressed in tumor-associated macrophages. Blockade of LIF promotes the induction of type I interferon and CXCL9 inducing the tumor infiltration of CD8 T cells. This results in the sensitization of the tumor to ICI. Importantly, we observed that patients with cervical cancer expressing high levels of LIF tend to be resistant to ICI. Conclusions: Our data show that the HPV virus induces the expression of LIF to provide a selective advantage to the tumor cell by generating local immunosuppression via the repression of type I interferon and CXCL9. Combinatory treatment with blocking antibodies against LIF and ICI could be effective against cervical cancer expressing high levels of LIF.
- 22 September 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (21) , e114719
IκB kinase‐α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage‐based anticancer therapy
Activation of the IκB kinase (IKK) complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-κB has remained elusive. Here, analysis of IKK-dependent substrates in CRC cells after UV treatment revealed that phosphorylation of BRD4 by IKK-α is required for its chromatin-binding at target genes upon DNA damage. Moreover, IKK-α induces the NF-κB-dependent transcription of the cytokine LIF, leading to STAT3 activation, association with BRD4 and recruitment to specific target genes. IKK-α abrogation results in defective BRD4 and STAT3 functions and consequently irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKK-α activity, BRD4, and the JAK/STAT pathway enhanced the therapeutic potential of 5-fluorouracil combined with irinotecan in CRC cells and is curative in a chemotherapy-resistant xenograft model. Finally, coordinated expression of LIF and IKK-α is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKK-α, BRD4, and JAK/STAT signaling with clinical relevance.
- 22 September 2023
- Published by Springer Nature in The EMBO Journal
- Vol. 42 (21) , e114719
IκB kinase‐α coordinates BRD4 and JAK/STAT signaling to subvert DNA damage‐based anticancer therapy
Activation of the IκB kinase (IKK) complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-κB has remained elusive. Here, analysis of IKK-dependent substrates in CRC cells after UV treatment revealed that phosphorylation of BRD4 by IKK-α is required for its chromatin-binding at target genes upon DNA damage. Moreover, IKK-α induces the NF-κB-dependent transcription of the cytokine LIF, leading to STAT3 activation, association with BRD4 and recruitment to specific target genes. IKK-α abrogation results in defective BRD4 and STAT3 functions and consequently irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKK-α activity, BRD4, and the JAK/STAT pathway enhanced the therapeutic potential of 5-fluorouracil combined with irinotecan in CRC cells and is curative in a chemotherapy-resistant xenograft model. Finally, coordinated expression of LIF and IKK-α is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKK-α, BRD4, and JAK/STAT signaling with clinical relevance.
- Open Access
IKKα kinase coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy
SUMMARY: Activation of the IKK kinase complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-κB has remained elusive. Analysis of IKK-dependent substrates after UV-treatment revealed that BRD4 phosphorylation by IKKα is required for chromatin-binding dynamics upon damage. Moreover, IKKα induces the NF-κB-dependent transcription of LIF leading to STAT3 activation, association of BRD4 to STAT3 and recruitment to specific target genes. IKKα abrogation results in defective BRD4 and STAT3 function leading to irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKKα activity or BRD4 and the JAK/STAT pathway enhanced the therapeutic potential of 5-FU plus irinotecan in CRC cells, and is curative in a chemotherapy-resistant CRC xenograft model. Coordinated expression of LIF and IKKα is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKKα, BRD4 and JAK/STAT signaling with clinical relevance.
Open AccessIKKα kinase coordinates BRD4 and JAK/STAT signaling to subvert DNA damage-based anticancer therapy
SUMMARY: Activation of the IKK kinase complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-κB has remained elusive. Analysis of IKK-dependent substrates after UV-treatment revealed that BRD4 phosphorylation by IKKα is required for chromatin-binding dynamics upon damage. Moreover, IKKα induces the NF-κB-dependent transcription of LIF leading to STAT3 activation, association of BRD4 to STAT3 and recruitment to specific target genes. IKKα abrogation results in defective BRD4 and STAT3 function leading to irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKKα activity or BRD4 and the JAK/STAT pathway enhanced the therapeutic potential of 5-FU plus irinotecan in CRC cells, and is curative in a chemotherapy-resistant CRC xenograft model. Coordinated expression of LIF and IKKα is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKKα, BRD4 and JAK/STAT signaling with clinical relevance.
- Open Access
- 8 May 2023
- Published by Springer Nature in Research Square
IKKα kinase coordinates BRD4 and STAT3 signaling to subvert DNA damage-based anticancer therapy
Activation of the IKK kinase complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-kB has remained elusive. Analysis of IKK-dependent substrates after UV-treatment revealed that BRD4 phosphorylation by IKKa is required for chromatin-binding dynamics upon damage. Moreover, IKKa induces the NF-kB-dependent transcription of LIF leading to STAT3 activation, association of BRD4 to STAT3 and recruitment to specific target genes. IKKa abrogation results in defective BRD4 and STAT3 function leading to irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKKa activity and JAK/STAT pathway enhanced the therapeutic potential of 5-FU plus irinotecan in CRC patient-derived organoids and is curative in a chemotherapy-resistant CRC xenograft model. Coordinated expression of LIF and IKKa is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKKa, BRD4 and JAK/STAT signaling with clinical relevance.
- 8 May 2023
- Published by Springer Nature in Research Square
Open AccessIKKα kinase coordinates BRD4 and STAT3 signaling to subvert DNA damage-based anticancer therapy
Activation of the IKK kinase complex has recurrently been linked to colorectal cancer (CRC) initiation and progression. However, identification of downstream effectors other than NF-kB has remained elusive. Analysis of IKK-dependent substrates after UV-treatment revealed that BRD4 phosphorylation by IKKa is required for chromatin-binding dynamics upon damage. Moreover, IKKa induces the NF-kB-dependent transcription of LIF leading to STAT3 activation, association of BRD4 to STAT3 and recruitment to specific target genes. IKKa abrogation results in defective BRD4 and STAT3 function leading to irreparable DNA damage and apoptotic cell death upon different stimuli. Simultaneous inhibition of BRAF-dependent IKKa activity and JAK/STAT pathway enhanced the therapeutic potential of 5-FU plus irinotecan in CRC patient-derived organoids and is curative in a chemotherapy-resistant CRC xenograft model. Coordinated expression of LIF and IKKa is a poor prognosis marker for CRC patients. Our data uncover a functional link between IKKa, BRD4 and JAK/STAT signaling with clinical relevance.
- Open Access
- 8 June 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (11) , 3410-3421
Sézary syndrome patient–derived models allow drug selection for personalized therapy
Current therapeutic approaches for Sézary syndrome (SS) do not achieve a significant improvement in long-term survival of patients, and they are mainly focused on reducing blood tumor burden to improve quality of life. Eradication of SS is hindered by its genetic and molecular heterogeneity. Determining effective and personalized treatments for SS is urgently needed. The present work compiles the current methods for SS patient–derived xenograft (PDX) generation and management to provide new perspectives on treatment for patients with SS. Mononuclear cells were recovered by Ficoll gradient separation from fresh peripheral blood of patients with SS (N = 11). A selected panel of 26 compounds that are inhibitors of the main signaling pathways driving SS pathogenesis, including NF-kB, MAPK, histone deacetylase, mammalian target of rapamycin, or JAK/STAT, was used for in vitro drug sensitivity testing. SS cell viability was evaluated by using the CellTiter-Glo_3D Cell Viability Assay and flow cytometry analysis. We validated one positive hit using SS patient–derived Sézary cells xenotransplanted (PDX) into NOD-SCID-γ mice. In vitro data indicated that primary malignant SS cells all display different sensitivities against specific pathway inhibitors. In vivo validation using SS PDX mostly reproduced the responses to the histone deacetylase inhibitor panobinostat that were observed in vitro. Our investigations revealed the possibility of using high-throughput in vitro testing followed by PDX in vivo validation for selective targeting of SS tumor cells in a patient-specific manner.
- 8 June 2022
- Published by American Society of Hematology in Blood Advances
- Vol. 6 (11) , 3410-3421
Open AccessSézary syndrome patient–derived models allow drug selection for personalized therapy
Current therapeutic approaches for Sézary syndrome (SS) do not achieve a significant improvement in long-term survival of patients, and they are mainly focused on reducing blood tumor burden to improve quality of life. Eradication of SS is hindered by its genetic and molecular heterogeneity. Determining effective and personalized treatments for SS is urgently needed. The present work compiles the current methods for SS patient–derived xenograft (PDX) generation and management to provide new perspectives on treatment for patients with SS. Mononuclear cells were recovered by Ficoll gradient separation from fresh peripheral blood of patients with SS (N = 11). A selected panel of 26 compounds that are inhibitors of the main signaling pathways driving SS pathogenesis, including NF-kB, MAPK, histone deacetylase, mammalian target of rapamycin, or JAK/STAT, was used for in vitro drug sensitivity testing. SS cell viability was evaluated by using the CellTiter-Glo_3D Cell Viability Assay and flow cytometry analysis. We validated one positive hit using SS patient–derived Sézary cells xenotransplanted (PDX) into NOD-SCID-γ mice. In vitro data indicated that primary malignant SS cells all display different sensitivities against specific pathway inhibitors. In vivo validation using SS PDX mostly reproduced the responses to the histone deacetylase inhibitor panobinostat that were observed in vitro. Our investigations revealed the possibility of using high-throughput in vitro testing followed by PDX in vivo validation for selective targeting of SS tumor cells in a patient-specific manner.